Pre‐clinical and clinical evaluation of the HYPERSCINT plastic scintillation dosimetry research platform for in vivo dosimetry during radiotherapy

Schoepper, Imke; Dieterich, Sonja; Trestrail, Earl A.; Kent, Michael S.

doi:10.1002/acm2.13551

Cited by 7 publications

(13 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Blue Physics Model 10 scintillation detector system performed well in all three tests. Results were similar to those obtained by Carrasco et al., 17 Schoepper et al., 31 and Beierholm et al., 30 with a slightly better RMS value for dose‐response linearity. In the latter test, the deviation from linearity was less than 0.6% for all MU supplied, except when 5 MU (0.92%) and 1 MU (1.19%) were delivered.…”

Section: Discussionsupporting

confidence: 89%

“…F I G U R E 1 1 2 × 2 cm 2 and 10 × 10 cm 2 profiles measured point by point with the Blue Physics scintillator, diamond detector, and PinPoint and Semiflex 3D ionization chambers. lar to those obtained by Carrasco et al, 17 Schoepper et al, 31 and Beierholm et al, 30 with a slightly better RMS value for dose-response linearity. In the latter test, the deviation from linearity was less than 0.6% for all MU supplied, except when 5 MU (0.92%) and 1 MU (1.19%) were delivered.…”

Section: Short-term Repeatability Dose-response Linearity Dose Rate D...supporting

confidence: 75%

“…Values of dose‐rate dependence presented less variation than the ones reported by Schoepper et al 31 and better RMS value than the one reported by Carrasco et al 17 . Measured dose percentage deviation values showed in Figure 8(b) resulted negative as the treatment dose rate,.…”

Section: Discussionmentioning

confidence: 58%

“…In any case, the differences in doses per field are compensated at the end of the treatment for both comparisons and the total treatment dose is measured with only 0.5% deviation respect to the average between the measured and calculated doses. Schoepper et al 31 . report dose differences between −1.67% and 3.15% for clinical patients, while Wootton et al 38 .…”

Section: Discussionmentioning

confidence: 99%

“…Temperature dependence results show that the scintillator is almost temperature independent, allowing it to 17,28,31,32 show different dependencies with the temperature that make it necessary to apply a correction factor, which is not necessary with the Blue Physics scintillator.…”

Section: Angular and Temperature Dependencementioning

confidence: 99%

See 4 more Smart Citations

Dosimetric characterization of a novel commercial plastic scintillation detector with an MR‐Linac

et al. 2023

View full text Add to dashboard Cite

Background: Plastic scintillators have been used as radiation detectors for the past few years, as they are water-equivalent and independent of the dose, dose rate, and angle of incidence. In addition, they are also independent of the presence of a magnetic field and could be used for in vivo dosimetry in an MR-Linac. With the advent of a new commercial scintillation detector, Blue Physics Model 10,its characterization has been performed on an MR-Linac with a view to future applications. Purpose: To perform the dosimetric characterization and study potential applications of a novel commercial plastic scintillation detector in a MR-Linac. Methods: Scintillation detector description, calibration procedure, short-term repeatability, dose-response linearity, dose-rate dependence, angular dependence, and temperature dependence have been studied. Percent-depth-dose (PDD) and beam profiles were measured for small fields and a standard field, as well as output factors, for comparison with other PTW detectors: a diamond diode and PinPoint and Semiflex 3D ionization chambers. The suitability of the plastic scintillator for in vivo dosimetry in a magnetic field has also been studied measuring the dose to a point in an anthropomorphic phantom while acquiring MR imaging. This measured dose was compared with that calculated with Monaco planning system and with that measured with a PTW Semiflex 3D chamber, the latter without acquiring MR images. Results: Short-term repeatability presented negligible variations (<0.4%) for 100 and 20 MU. Similar results were obtained for dose-response linearity and dose-rate dependence. A small angular dependence was determined, while the scintillator resulted practically independent of the temperature. PDDs showed excellent agreement except in the build-up region, and calculated penumbras with the profiles given by the scintillator were between the ones obtained with the diamond detector and the PinPoint ionization chamber. Measured OF with the scintillator were the highest between all detectors, 1.26% higher than the value obtained with the microdiamond for the smallest field measured, 0.5 × 0.5 cm 2 . Finally, the total dose to a point measured with the scintillator was 0.51% higher compared to that calculated by the planning system. Conclusion:The Blue Physics model 10 scintillation system showed excellent dosimetric characteristics. Its response independent of the temperature and the presence of a magnetic field make it suitable for in vivo dosimetry in an MR-Linac while acquiring MR images, which could solve the impossibility of performing a dosimetric QA for each adapted plan. Furthermore, its temporalThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Short-term Repeatability Dose-response Linearity Dose Rate D...supporting

confidence: 75%

Section: Discussionmentioning

confidence: 58%

Section: Discussionmentioning

confidence: 99%

Section: Angular and Temperature Dependencementioning

confidence: 99%

See 3 more Smart Citations

Dosimetric characterization of a novel commercial plastic scintillation detector with an MR‐Linac

et al. 2023

View full text Add to dashboard Cite

show abstract

Pre‐clinical and clinical evaluation of the HYPERSCINT plastic scintillation dosimetry research platform for in vivo dosimetry during radiotherapy

Schoepper

Dieterich

Trestrail³

et al. 2022

J Applied Clin Med Phys

Self Cite

View full text Add to dashboard Cite

Purpose The purpose of this work is to evaluate the Hyperscint‐RP100 scintillation dosimetry research platform (Hyperscint‐RP100, Medscint Inc., Quebec, QC, Canada) designed for clinical quality assurance (QA) for use in in vivo dosimetry measurements. Methods The pre‐clinical evaluation of the scintillator was performed using a Varian TrueBeam linear accelerator. Dependency on field size, depth, dose, dose rate, and temperature were evaluated in a water tank and compared to calibration data from commissioning and annual QA. Angularity was evaluated with a 3D printed phantom. The clinical evaluation was first performed in two cadaver dogs, and then in three companion animal dogs receiving radiation therapy for nasal tumors. A treatment planning CT scan was performed for cadavers and clinical patients. Prior to treatment, the probe was inserted into the radiation field. Radiation was then delivered and measured with the scintillator. For cadavers, the treatment was repeated after making an intentional shift in patient position to simulate a treatment error. Results In the preclinical measurements the dose differed from annual measurements as follows: field size −0.77 to 0.43%, depth dose −0.36 to 1.14%, dose −0.54 to 2.93%, dose rate 0.3 to 3.6%, and angularity −1.18 to 0.01%. Temperature dependency required a correction factor of 0.11%/°C. In the two cadavers, the dose differed by −1.17 to 0.91%. The device correctly detected the treatment error when the heads were intentionally laterally shifted. In three canine clinical patients treated in multiple fractions, the detected dose ranged from 98.33 to 103.15%. Conclusion Results of this new device are promising although more work is necessary to fully validate it for clinical dosimetry.

show abstract

A feasibility study of dosimetry for breast cancer radiotherapy based on body surface changes

Deng,

Qiu,

Zhong

et al. 2024

Medical Physics

View full text Add to dashboard Cite

BackgroundThe requirement for precise and effective delivery of the actual dose to the patient grows along with the complexity of breast cancer radiotherapy. Dosimetry during treatment has become a crucial component of guaranteeing the efficacy and security.PurposeTo propose a dosimetry method during breast cancer radiotherapy based on body surface changes.MethodsA total of 29 left breast cancer radiotherapy cases were retroactively retrieved from an earlier database for analysis. Non‐rigid image registration and dose recalculation of the planning computed tomography (CT) referring to the Cone‐beam computed tomography were performed to obtain dose changes. The study used 3D point cloud feature extraction to characterize body surface changes. Based on the correlation proof, a mapping model is developed between body surface changes and dose changes using neural network framework. The MSE metrics, the Euclidean distances of feature points and the 3D gamma pass rate metric were used to assess the prediction accuracy.ResultsA strong correlation exist between body surface changes and dose changes (first canonical correlation coefficient = 0.950). For the dose deformation field and dose amplitude difference in the test set, the MSE of the predicted and actual values were 0.136 pixels and 0.229 cGy, respectively. After deforming the planning dose into a deformed one, the feature points’ Euclidean distance between it and the recalculated dose changes from 9.267 ± 1.879 mm to 0.456 ± 0.374 mm. The 3D gamma pass rate of 90% or higher for the 2 mm/2% criteria were achieved by 80.8% of all cases, with a minimum pass rate of 75.9% and a maximum pass rate of 99.6%. Pass rate for the 3 mm/2% criteria ranged from 87.8% to 99.8%, with 92.3% of the cases having a pass rate of 90% or higher.ConclusionsThis study provides a dosimetry method that is non‐invasive, real‐time, and requires no additional dose for breast cancer radiotherapy.

show abstract

Pre‐clinical and clinical evaluation of the HYPERSCINT plastic scintillation dosimetry research platform for in vivo dosimetry during radiotherapy

Cited by 7 publications

References 15 publications

Dosimetric characterization of a novel commercial plastic scintillation detector with an MR‐Linac

Dosimetric characterization of a novel commercial plastic scintillation detector with an MR‐Linac

Pre‐clinical and clinical evaluation of the HYPERSCINT plastic scintillation dosimetry research platform for in vivo dosimetry during radiotherapy

A feasibility study of dosimetry for breast cancer radiotherapy based on body surface changes

Contact Info

Product

Resources

About